• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$12.15 $0.76 (6.67%)

REAL-TIME: Last trade at

MAP Pharmaceuticals

NASDAQ:MAPP

Jump to this page for:

Related Resources

Canaccord Genuity Maintains a 'Buy' on MAP Pharmaceuticals (MAPP); Q1 EPS A Non-event; Focus Remains on LEVADEX

5/7/2012 by StreetInsider.com

MAP Pharmaceuticals sees collaboration revenues $2.6M for remainder of year

5/4/2012 by Theflyonthewall.com

MAP Pharmaceuticals, Inc. (MAPP) Posts Wider than Expected Q1 Loss

5/4/2012 by StreetInsider.com

MAP Pharmaceuticals to meet with FDA about LEVADEX in Q2

5/4/2012 by Theflyonthewall.com

MAP Pharmaceuticals reports Q1 EPS (58c), consensus (39c)

5/4/2012 by Theflyonthewall.com

Robbins Umeda LLP Announces an Investigation of MAP Pharmaceuticals, Inc.

5/2/2012 by StockWatch

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

5/1/2012 by PR Newswire

Research and Markets: MAP Pharmaceuticals: PharmaVitae Report

4/30/2012 by PharmiWeb.com - UK

Research and Markets: MAP Pharmaceuticals: PharmaVitae Report

4/30/2012 by Business Wire

MAP Pharma: Still Potentially A Good Short Sell

4/17/2012 by Seeking Alpha

MAP Pharmaceuticals, Inc. to Meet FDA to Discuss Manufacturing Issues; Provides Update on LEVADEX

4/13/2012 by BioSpace

Map Pharmaceuticals Plans FDA Meeting To Discuss Manufacturing Issues

4/12/2012 by NASDAQ

MAP Pharma (MAPP) Gets Meeting with FDA, U.S. Patent for LEVADEX

4/12/2012 by StreetInsider.com

MAP Pharmaceuticals submits request to FDA regarding Levadex

4/12/2012 by Theflyonthewall.com

MAP Pharmaceuticals Provides Update on LEVADEX® Program

4/12/2012 by PR Newswire

Lazard Capital to host a bus tour

4/3/2012 by Theflyonthewall.com

Map Pharmaceuticals: The Levadex Levitation

4/3/2012 by Seeking Alpha

Summer Street's biotech analyst holds an analyst/industry conference call

3/30/2012 by Theflyonthewall.com

Biotech Stock Mailbag: MAP Pharma, Affymax

3/30/2012 by TheStreet.com

MAP Pharma falls on 4Q loss and restatement

3/29/2012 by Bioscience Technology

Pre-market Movers For March 29 (BBY, LORL, PSS, RHT, ILMN, SHLD, MAPP, RIMM)

3/29/2012 by RTTNews

MAP Pharmaceuticals, Inc. (MAPP) Reports Q4 Loss of 45c/Share; to Restate Interim Statements for First 3 Qtrs. of 2011

3/29/2012 by StreetInsider.com

MAP Pharmaceuticals reports Q4 EPS (45c), consensus (31c)

3/29/2012 by Theflyonthewall.com

MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results

3/29/2012 by PR Newswire

Top Stock Alerts for Day Traders: JDS Uniphase, MAP Pharmaceuticals, Alcoa, KB Home, Renren, and PulteGroup

3/28/2012 by PR Newswire

Canaccord Genuity Reiterates a 'Buy' on MAP Pharmaceuticals (MAPP); CRL Disappointing, but Visibility Encouraging

3/28/2012 by StreetInsider.com

Map Pharmaceuticals Drops on Migraine Drug Rejection

3/27/2012 by Minyanville

MAP Pharmaceuticals FDA letter could de-risk approval, says Leerink

3/27/2012 by Theflyonthewall.com

MAP Pharmaceuticals volatility decreases after migraine drug rejection

3/27/2012 by Theflyonthewall.com

Map Pharmaceuticals (MAPP) To See Downside Pressure As Its Migraine Drug Fails To Get FDA Nod

3/27/2012 by iStockAnalyst

MAP Pharmaceuticals falls 12.9%

3/27/2012 by Theflyonthewall.com

Pre-market Movers For March 27-WAG, MKC, ISTA, APOL, DG, MAPP, SCMF, TRGT, ZSTN

3/27/2012 by RTTNews

MAP complete response letter implies modest delay, says Deutsche Bank

3/27/2012 by Theflyonthewall.com

MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA

3/26/2012 by PR Newswire

Signs Point to MAP Pharma Drug Rejection

3/26/2012 by TheStreet.com

MAP Pharma (MAPP) Shares Halted; FDA Decision on Levadex Expected; Watch Nektar (NKTR), Allergan (AGN)

3/26/2012 by StreetInsider.com

MAP Pharmaceuticals trading halted, pending news

3/26/2012 by Theflyonthewall.com

Affymax, Inc., MAP Pharmaceuticals, Inc. Drug Approvals Would Net Royalty Bounty for Nektar Therapeutics (CA)

3/26/2012 by BioSpace

MAP Pharmaceuticals (MAPP) April put volatility elevated at 187 into PDUFA

3/26/2012 by StreetInsider.com

MAP Pharmaceuticals moves higher in pre-market, resistance at $16.99

3/26/2012 by Theflyonthewall.com
See More Articles...